Alaunos Therapeutics (TCRT) Competitors $2.64 +0.10 (+3.90%) As of 01:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. LSTA, CMMB, PASG, BFRG, ALLR, TXMD, NRSN, PMN, SNYR, and ALVRShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Lisata Therapeutics (LSTA), Chemomab Therapeutics (CMMB), Passage Bio (PASG), Bullfrog AI (BFRG), Allarity Therapeutics (ALLR), TherapeuticsMD (TXMD), NeuroSense Therapeutics (NRSN), ProMIS Neurosciences (PMN), Synergy CHC Corp. (Uplisting) (SNYR), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Lisata Therapeutics Chemomab Therapeutics Passage Bio Bullfrog AI Allarity Therapeutics TherapeuticsMD NeuroSense Therapeutics ProMIS Neurosciences Synergy CHC Corp. (Uplisting) AlloVir Lisata Therapeutics (NASDAQ:LSTA) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations. Do analysts prefer LSTA or TCRT? Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 502.41%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Lisata Therapeutics is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in LSTA or TCRT? Lisata Therapeutics received 7 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 93.33% of users gave Lisata Therapeutics an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote. CompanyUnderperformOutperformLisata TherapeuticsOutperform Votes1493.33% Underperform Votes16.67%Alaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% Do institutionals & insiders have more ownership in LSTA or TCRT? 8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to LSTA or TCRT? In the previous week, Alaunos Therapeutics had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for Lisata Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.50 beat Lisata Therapeutics' score of 0.00 indicating that Alaunos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lisata Therapeutics Neutral Alaunos Therapeutics Very Positive Is LSTA or TCRT more profitable? Lisata Therapeutics' return on equity of -51.19% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lisata TherapeuticsN/A -51.19% -45.16% Alaunos Therapeutics N/A -267.77%-209.18% Which has better valuation and earnings, LSTA or TCRT? Lisata Therapeutics has higher revenue and earnings than Alaunos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLisata Therapeutics$1M21.45-$20.84M-$2.30-1.08Alaunos Therapeutics$10K432.80-$35.14MN/AN/A Which has more volatility & risk, LSTA or TCRT? Lisata Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.08, meaning that its stock price is 208% less volatile than the S&P 500. SummaryLisata Therapeutics beats Alaunos Therapeutics on 11 of the 15 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.33M$6.49B$5.33B$8.43BDividend YieldN/A2.64%5.21%4.11%P/E RatioN/A9.1226.8519.75Price / Sales432.80256.15388.74118.67Price / CashN/A65.8538.2534.62Price / Book0.676.436.764.50Net Income-$35.14M$144.21M$3.23B$248.32M7 Day Performance-6.42%2.25%1.71%0.48%1 Month Performance9.96%4.39%11.16%13.08%1 Year Performance-74.63%-2.71%17.17%7.36% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics1.1065 of 5 stars$2.64+3.9%N/A-76.3%$4.33M$10,000.000.0040Positive NewsEarnings ReportLSTALisata Therapeutics2.8024 of 5 stars$2.15-3.2%$15.00+597.7%-16.9%$18.52M$1M-0.8630CMMBChemomab Therapeutics3.3109 of 5 stars$1.28+3.2%$9.00+603.1%+68.3%$18.38MN/A-1.2820Earnings ReportPASGPassage Bio2.1018 of 5 stars$0.29-5.3%$7.50+2,467.6%-76.5%$18.15MN/A-0.25130Gap UpBFRGBullfrog AI0.4521 of 5 stars$1.88+6.2%N/A-40.1%$17.70M$60,000.00-2.214Positive NewsALLRAllarity Therapeutics0.1338 of 5 stars$1.04+1.5%N/A-93.8%$17.67MN/A0.0010Analyst UpgradeTXMDTherapeuticsMD0.907 of 5 stars$1.52+2.7%N/A-30.1%$17.59M$1.76M0.00420News CoverageAnalyst ForecastNRSNNeuroSense Therapeutics2.4467 of 5 stars$1.27+15.4%$14.00+1,003.0%+19.0%$17.35MN/A-1.9810Gap UpHigh Trading VolumePMNProMIS Neurosciences1.6382 of 5 stars$0.53+5.8%$4.50+749.1%-70.7%$17.33MN/A-5.305Gap UpSNYRSynergy CHC Corp. (Uplisting)2.573 of 5 stars$1.97+7.5%$10.00+408.2%N/A$17.22M$34.83M0.0040Trending NewsEarnings ReportAnalyst RevisionGap DownALVRAlloVirN/A$3.38-2.9%N/A-81.8%$17.05MN/A-0.17110High Trading Volume Related Companies and Tools Related Companies Lisata Therapeutics Alternatives Chemomab Therapeutics Alternatives Passage Bio Alternatives Bullfrog AI Alternatives Allarity Therapeutics Alternatives TherapeuticsMD Alternatives NeuroSense Therapeutics Alternatives ProMIS Neurosciences Alternatives Synergy CHC Corp. (Uplisting) Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredAI Bloodbath Coming on June 1st?If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRT Stock Free TCRT Stock Alerts